Monthly formulary amendments – April 2026
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in April 2026.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Monthly Horizon Scanning Report – April 2026
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licences, significant new guidance, and decisions that have been made by recognised bodies.
This edition covers new and updated medicines and guidance published in March 2026.
This information is produced for use by NHS healthcare professionals.
Comparison of DOACs for Atrial Fibrillation
Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area.
Several direct oral anticoagulants (DOACs) are licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF). This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.
This publication was comprehensively updated in May 2025 to reflect changes to the respective SPCs and/or updated references. Where possible sections have been simplified and amended to reduce duplication and to consolidate some of the information. A contents page with hyperlinks to each section was added for easier navigation.
Medicines value tracker – Shower and Bath emollients; opportunity savings realised
The purpose of the Medicines value bulletin tracker publications are to support ICBs in monitoring progress and identifying remaining potential opportunity savings, for the Medicines value opportunities already identified in the RDTC Medicines Value Bulletin series. The MVB tracker publications for shower and bath emollients cover all 7 ICBs across the North of England. Please select the appropriate version for your region below.
Monthly formulary amendments – April 2025
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in April 2025.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Budget impact of emollient bath and shower preparations
The purpose of this bulletin is to promote cost effective prescribing by highlighting the lack of evidence on the efficacy of emollient bath and shower preparations for the management of atopic eczema, in line with updated NICE guidance. It considers the potential savings that could be achieved with reduced prescribing of these products across the ICSs in the North East & Yorkshire region and Greater Manchester.
This publication was updated in April 2025 – First published in February 2023
Medicines value tracker – Metformin 1g tablets; opportunity savings realised
The purpose of the Medicines value bulletin tracker publications are to support ICBs in monitoring progress and identifying remaining potential opportunity savings, for the Medicines value opportunities already identified in the RDTC Medicines Value Bulletin series. The MVB tracker publications for Metformin 1g IR tablets cover all 7 ICBs across the North of England. Please select the appropriate version for your region below.
Monthly Horizon Scanning Report – April 2025
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Monthly formulary amendments – March 2025
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in March 2025.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Monthly formulary amendments – April 2024
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in April 2024.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.